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1. Introduction  
The recognition of pathogenic antigens as foreign particles by adaptive immune cells 
induces T and B lymphocytes to start defensive humoral and cellular reaction. Latest 
research revealed that proteins and some lipids are the main molecules inducing protective 
T cell responses during microbial infections while polysaccharides which are important 
components of microbial pathogens and many vaccines were not regarded as important 
antigens. However, research regarding the role of the adaptive immune system by 
polysaccharides gained interest only recently. Traditionally, polysaccharides were 
considered to be T cell-independent antigens that did not directly activate T cells or induce 
protective immune responses, but chemically modified polysaccharides, namely 
zwitterionic polysaccharides (ZPSs) were recently found highly immunogenic. Therefore, in 
this chapter we will discuss the role of zwittrionized polysaccharides in immune reaction 
induction and their immunostimulatory effect in cancer patients. Several studies were 
conducted to use ZPSs to induce vigorous immune response and to establish 
immunostimulatory or immunomodulatroy effect which can be used in cancer 
immunotherapy. Bacterial ZPSs that are naturally zwitterionic or those that were artificially 
zwitterionized were recently identified as potent immune regulators. The 
immunomodulatory effect of ZPSs requires antigen processing and presentation by antigen 
presenting cells, the activation of CD4 T cells and subpopulations of CD8 T cells and the 
modulation of host cytokine responses.  
In addition, a recent model research done by our team will be presented in this chapter. This 
research introduced, in a breakthrough approach, zwitterionic motifs experimentally into 
polysaccharides of pneumo-23 vaccine converting these polysaccharides into effective 
immunostimulatory agent in immunosuppressed cancer patients. This study intended to 
assess the in vitro immunostimulatory effect of zwitterionized penumoccocal vaccine 
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compared with the nonzwitterionized commercial pneumo-23 vaccine. The in vitro 
immunostimulatory potential of zwitterionized penumoccocal vaccine was clearly observed 
in cancer immunosuppressed patients as well as, to a lesser extent, healthy control subjects, 
stimulating the synthesis of core cytokines of T-helper 1, and primarily inducing CD4+ and 
CD8+T cells. These studies collectively open the door wide for a new field for effective 
cancer immunotherapy. 
2. The role of ZPS in eliciting immune response  
The majority of the natural polysaccharide molecules consist of anionic sugar molecules 
which fail to activate T cells, and do not induce B-cell antibody isotype switching (Tzianabos 
et al., 1992). However, it was identified that a small group of bacterial polysaccharides 
carries both positive and negative charges in the same repeating sugar molecules which 
were accordingly called zwitterionic polysaccharides (ZPSs) (Baumann et al., 1992; 
Tzianabos et al., 1992; Coyne et al., 2000; Kalka-Moll, et al., 2001). Unlike most of bacterial 
polysaccharides, zwitterionic PS possess both positive and negative ions, which in turn 
found to be able to trigger T cell-dependent immune response, initiate class switching and 
affinity maturation of immunoglobulins, and induce long-term memory immunity 
(Gallorini et al., 2007; Cobb & Kasper, 2005; Wack et al., 2008; Richard & Amyes, 2004). 
Polysaccharides with both positively and negatively charged sugar molecules, unlike 
negatively charged polysaccharides, are able to stimulate both CD4 and CD8 T cells as well 
as antigen presenting cells of the adaptive immune system. This feature shows that 
molecules other than proteinaceous antigens are capable of activating conventional  
ǂǃT cells.  
However, development of specific T-Cell receptor (TCR) transgenic mouse models are 
required to understand the selection and development of ZPS-specific T cells. These cells 
may be more enriched in the mucosae as ZPS-producing bacteria such as Bacteroides fragilis 
(B. fragilis) and Streptococcus. Pneumoniae (S. pneomoniae) are contained within the commensal 
flora of the gut and upper respiratory track, respectively. ZPSs display an extended right-
handed helix structure in which two repeating sugar units per turn form grooves with 
positive charges exposed on the outer surface (Wang et al., 2000). Due to this unique 
structure, ZPSs possess immunomodulatory activities, unlike other polysaccharides. 
Experimental studies in rats and mice have shown that intraperitoneal challenges with ZPSs 
induced vigorous pathogenic conditions, such as intra-abdominal abscesses which never 
happen in response to traditional polysaccharides (Tzianabos et al., 2000; Mazmanian et al., 
2005). When ZPSs are accidently introduced into a sterile area, such as the peritoneal cavity 
during intra-abdominal surgical procedures when abdominal contents can spill into the 
peritoneal cavity, or by intraperitoneal inoculation with ZPS and a sterile cecal adjutant, a 
rapid recruitment of ZPS-specific, proinflammatory CD4 T cells may be induced. This 
recruitment of CD4 T cells together with other innate cells results in the generation of intra-
abdominal abscess, a defensive mechanism of the body to contain the infection. Recent 
studies have shown that ZPS-mediated intraabdominal abscess induction depends on ZPS 
processing and presentation on MHC class-II molecules by APCs for recognition and 
activation of CD4 T cells (Stephen et al., 2010).  
ZPS-specific T cells are in constant contact with ZPS presented by antigen presenting cells 
(APCs) of the mucosal immune system. Accordingly, the steady-state presentation of this 
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unique immunomodulatory microbial antigen is beneficial to our immune system as it can 
play pivotal role in shaping a functionally competent, immune system which is a must 
element in any successful immunotherapy. Interestingly, upon subcutaneous inoculation, 
ZPSs induce, in a unique manner, both anti-inflammatory and immunosuppressive T cells at 
the same tine. The stimulated population of cells includes both regulatory CD4 and CD8 T 
cells, which secrete the immunosuppressive cytokine IL-10. Thus, the same immunogen can 
elicit both proinflammatory and anti-inflammatory responses dependent upon the route and 
mode of administration; this can be regarded as one of the reasons that ZPSs are able to play 
essential role in modulating/regulating immune system of humans. 
3. Mechanisms of immune induction and regulation by ZPSs 
ZPSs were found to possess immunostimulatory functions. The in vitro stimulation of 
human and murine CD4 T cells with ZPSs induces cellular proliferation and inhibits 
apoptosis of immune cells (Stephen et al., 2005; Groneck et al., 2009). And this activity of 
ZPSs was found to be conducted mainly via T cell receptor (TCR). In addition, co-
stimulatory signals were also found necessary to induce remarkable T-cell responses to 
ZPSs; the activation of CD4 T cells by ZPS is found to be dependent on a several 
costimulatory factors. It was found that ZPSs can interact with lymphocytes and antigen 
presenting cells by particular mechanism(s). ZPSs possess specific immunostimulatory 
activity, leading to direct activation of antigen-presenting cells (APCs) through Toll-like 
receptor 2 (TLR2) and T-cell receptors (TCR) on the surface of T cells in co-culture systems. 
ZPS are therefore, considered TLR2 and TCR agonists, able to activate human and mouse 
APCs. Since T-regulatory cells and other T-cell subsets express TLR2, and TLR2 engagement 
modifies functionality and activation state of these cells, it is speculated that most effects 
induced by natural and chemically derived ZPS may be explained by their TLR2 and TCR 
agonist properties. Moreover, the presentation of fragmented ZPSs by MHC-class II 
molecules shows that ZPS-mediated T-cell activation is mediated by non-specific, 
generalized TCR recognition. Vǃ chain repertoire analyses of ZPS-stimulated T-cell 
populations showed that a broad repertoire of subfamilies, including all of the Vǃ 
subfamilies, was used more than specific Vǃ genes (Stingele et al., 2004; Groneck et al., 
2009). Therefore, the oligoclonal activation of T cells by ZPS seemed highly probable. 
Clonotype mapping of T cells that were stimulated in vitro with ZPSs showed oligoclonal T 
cell expansion. This nonrestricted Vǃ usage indicates possible ZPS recognition by the CDR3 
antigen-binding domain of the TCR. After TCR stimulation, CD69 is rapidly upregulated by 
the Ras-MAP kinase signaling pathway (D’Ambrosio et al., 1994); this implies to a notion 
that this pathway may be involved in ZPS-mediated T-cell activation (Stephen et al., 2010). 
However, no solid clues suggest the ability of ZPSs to stimulate gamma-delta T 
lymphocytes, NK or NKT cells.  
4. The immunological role of bacterial ZPSs  
Pathogenic strains of bacteria, such as B. fragilis, S. pneumoniae, and S. aureus, produce one of 
the most potent ZPSs in nature (Kolka-Moll et al., 2002); for this reason, bacterial ZPSs offer 
unique opportunity to exploit their extraordinary potential in stimulating or modulating 
immune system of humans. The capsular polysaccharide antigens PSA of B. fragilis (NCTC 
9343 and 638R) (Kolka-Moll et al., 2001) and Sp1 of S. pneumoniae serotype 1 (Kolka-Moll et 
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al., 2002) are the most widely studied ZPSs. Intra-abdominal abscess formation, which 
commonly occurs during secondary peritonitis and abdominal surgeries, is actually a ZPS-
based protective mechanism used by the body to limit the spread of microbial pathogens. 
Initially, bacterial ZPS-induced pathologies were shown to be T-cell dependent. In those 
experiments, T-cell-deficient mice were unable to form abscesses after inoculations with 
bacterial ZPSs (Shapiro et al., 1986). Further experiments with ǂ/ǃTCR-knockout mice 
revealed that immune response towards bacterial ZPSs were dependent on ǂ/ǃ TCR+ T 
cells (Chung et al., 2003). The activation of CD4 T cells is required for ZPS-mediated intra-
abdominal abscess induction because mice lacking CD4 T cells failed to develop abscesses 
(Chung et al., 2003). As abscess formation was inhibited by the transfer of T cells from 
animals that were immunized with ZPS, these results suggest that abscess inductions and 
protection in the presence of ZPS are likely mediated by T-cell components of the adaptive 
immune system. The immunomodulatory effects of ZPSs require both positive and negative 
charge motifs as neutralization of a single charge motif abrogates the biological activities of 
ZPSs in triggering elaborative immune response and in stimulating immune cells altogether 
(Stephen et al., 2010). In this regard, it was found that the conversion of a nonzwitterionic 
bacterial molecule into a zwitterion makes the molecule biologically active just like the 
natural zwitterionic molecules (Gallorini et al., 2009; Stephen et al., 2010). However, 
bacterial ZPSs exert both wanted and unwanted actions, namely immunostimulatory/ 
immunomodulatory action and vigorous antigen-based immune response, respectively. 
This provided evidence for the justification of creating novel approaches for converting 
bacterial non-ZPSs into ZPSs molecules using chemical in-laboratory methods in a way 
strengthening their immunostimulatory effect and at the same time lowering their antigen-
based immune reaction induction.  
5. Model study for the experimentally zwitterionized bacterial 
polysaccharides to induce immunostimulatory effect in immunosuppressed 
cancer patients 
The unique effect of zwitterionized bacterial polysaccharides as a potent in vitro 
immunostimulatory agent for immunosuppressed cancer patients was investigated in a 
novel study. The introduction of zwitterionic motifs into some of bacterial capsular 
polysaccharides turn these modified polysaccharides into moderately immunogenic and 
highly immunostimulatory agents. This study was conducted to assess the in vitro 
immunogenic and immunostimulatory effect of novel zwitterionized polysaccharides of the 
commercial pneumo-23 vaccine. In vitro proliferation, ELISA-based in vitro cytokine 
synthesis (IL-2, IFN-Ǆ, and IL-10), and immunofluorescence microscopy-based immune 
profiling (CD4+, CD8+, and CD21+ cells) assays were used to evaluate the 
immunostimulatory effect of 48h of zwitterionized pneumo-23 encounter with peripheral 
blood mononuclear cells (PBMC) of immunosuppressed cancer (CA) patients and healthy 
control subjects (HC) in comparison with PBMC exposed to Concanavalin A (Con A), the 
positive control, and to phosphate buffered saline (PBS), the negative control. 
Zwitterionized pneumo-23, induced remarkable proliferation of PBMC in both CA and HC 
groups, induced in vitro synthesis of IL-2 and IFN-Ǆ but not IL-10 in CA and borderline 
increase in IFN-Ǆ and IL-10 in HC group, and expanded CD4+, CD8+, and CD21+ 
lymphocytes in CA rather than HC group. On contrary, Con A induced proliferation in HC 
more than CA group, induced only IL-2 synthesis and expanded only CD4+ cells in HC 
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rather than CA group. Therefore, in this regard, it was concluded that a unique in vitro 
immunostimulatory potential of zwitterionized pneumo-23 vaccine was observed on PBMC 
of immunosuppressed more than immunocompetent subjects, stimulating the synthesis of 
core cytokines of T-helper 1, and inducing the CD8+ T cells, which are most probably CD8+ 
cytotoxic T-cells rather than suppressor cells. Accordingly, introducing zwitterionic motifs 
into polysaccharides of the commercial penumo-23 vaccine turned it into a unique and 
potent immunostimulator reverting suppressed immune cells back into normal levels.  
Pneumo-23 is a polyvalent pneumococcal polysaccharide vaccine (Pasteur Merieux 
Connaught, 2004). This vaccine was designed mainly to confer immunity against severe 
pneumococcal infections in elderly patients and those who underwent splenectomy as part 
of a management of various hematological disorders, renders the patients unsusceptible to 
the development of overwhelming sepsis by Streptococcus pneumoniae (Pasteur Merieux 
Connaught, 2004; Rybachenko et al., 2009; vad der Harst, 2007; Kazancioglu et al., 2000). 
Pneumo-23 is a clear, colorless liquid prepared from purified pneumococcal capsular 
antigens. Each dose of 0.5 mL contains purified S. pneumoniae polysaccharides (PS), 25 µg of 
each of the included 23 serotypes (Rybachenko et al., 2009). Although pneumo-23 is 
composed of non- T cell-dependent polysaccharides, it was observed that pneumo-23 
vaccine when is given to elderly people, or immunosuppressed patients, their immune 
response, in unexplained manner, was moderately enhanced non-specifically in addition to 
the immune protection achieved against pneumococcal infection(Rybachenko et al., 2009; 
vad der Harst, 2007; Kazancioglu et al., 2000). In addition, a recent study revealed another 
immune enhancing feature of pneumo-23 vaccine stating that pneumo-23 vaccine enhanced 
the opsonization and sustained normal compliment components of C3 and C4 in elderly 
cancer patients after splenectomy Uslu et al., 2006). This might be attributed to the fact that 
some of pneumo-23 PS is zwitterionic substances such as polysaccharides of type 1 
pneumococci (Gallorini et al., 2007).  
Although many studies discussed the specific immunogenicity of pmeumo-23 vaccine 
against pneumococcal bacterial serotypes in elderly or in HIV-infected patients (de Greef et 
al., 2007; Peetermans et al., 2005; Sumitani et al., 2008; Valenzuela et al., 2007), very few 
reports gave remarks on the unexplained potential of pneumo-23 to exert non-specific, 
generalized, immunostimulating effect and non-specific protection against microbes rather 
than pneumococci. A study revealed that the protection of pneumo-23 vaccine after 
splenectomy was perfect against the sepsis of many bacteria other than pneumococci which 
indicated a dubious role of the non-specific immunostimulatory effect of pneumo-23 vaccine 
in protecting subjects against bacterial infection in addition to its specific anti-pneumococcal 
infection (Uslu et al., 2005). Nevertheless, our team examined the possible in vitro 
immunostimulatory effect of the commercial pneumo-23 vaccine on human peripheral 
blood mononuclear cells (PBMC); the results showed some immunostimulatory potential of 
penumo-23 but it did not reach significant levels [data not shown]. This was predicted as the 
majority of pneumo-23 polysaccharides are T cell-independent substances except for small 
portion, serotype 1, which possess T cell-dependent zwitterionic motifs (Gallorini et al., 
2007; Cobb & Kasper, 2005). Since the commercial pneumo-23 is a pure polysaccharides 
mixture and unlikely to possess TLR ligands, accordingly, it was believed that the observed 
slight immunostimulatory effect of the commercial pneumo-23 in the preliminary study of 
our team and in other studies might belong to the presence of low level of zwitterionic 
motifs in pneumo-23 vaccine which provide evidence that if polysaccharides of pneumo-23 
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vaccine were zwitterionized, then this might issue in a very potent and unique bacterial 
ZPSs that is able to modulate and stimulate immune system of immunosuppressed and 
debilitated human patients. Therefore, it was hypothesized that introducing zwitterionic 
motifs into polysaccharides of pneumo-23 vaccine might render it a potent and effective 
immunostimulatory agent. In the current research, polysaccharides of the commercial 
pneumo-23 vaccine were modified chemically by adding zwitterionic motifs. The ability of 
zwitterionized pneumo-23 vaccine to trigger T cell-dependent immunostimulatory effect on 
PBMC of immunosuppressed cancer patients in comparison with healthy control subjects 
was scrutinized.  
5.1 Patients and methods  
5.1.1 The research population 
Since, cancer (CA) itself and the related chemotherapy are considered as a well-known 
condition of immunosuppression (Whiteside, 2006), three kinds of common CA were 
involved in this study, namely, lung, head and neck, and colorectal cancers. Sixty five 
immunosuppressed cancer patients of age ranged 42 to 62 years were involved in this study 
including 42 men with lung (22), head and neck (11), and colorectal (9) cancers and 23 
women with lung (13), colorectal (7), and head and neck (3) cancers. They were selected out 
of 94 cancer patients after excluding the non-confirmed cases of immunosuppression. The 
selection criteria of the involved cancer patients were: confirmed diagnosis of advanced 
cancer (stages III and IV), pre-operative, immunosuppressed, engaged regularly in 
chemotherapy, 6 weeks interval from the last chemotherapy. The selection was done 
without any bias to certain type of the involved cancer types. This study was conducted in 
the period from November 2006 to February 2009. Cancer patients were retrieved from a 
number of central hospitals in Malaysia, Kuala Lumpur. The immunosuppression status of 
cancer patients was checked twice. First, the clinical presentation of patients which revealed 
patients’ high susceptibility to frequent infections, patients’ lymphopenia in complete blood 
count, and state of hypo-Ǆ-globulinemia where serum IgG < 250 mg/dL, and serum IgA <5 
mg/dL. Second, the immunosuppression status was confirmed by the conducted assays of 
the current study.  
On the other hand, 100 age- and sex- matched healthy control (HC) were selected who 
attended hospitals for minor traumatic therapy. Medical examination was done for HC as well 
as their medical records were retrieved. They showed no current or previous major illness, no 
cancer, and normal blood and biochemical laboratory tests, namely erythrocyte sedimentation 
rate, complete blood count, liver function test, kidney function tests, and total serum proteins. 
Blood samples were taken from CA and HC groups after obtaining full written consent. 
Withdrawn blood was held in heparinized tubes for later isolation of PBMC. Permission was 
granted from the regional committee of ethics for biomedical research. 
5.1.2 Zwitterionisation of pneumo-23 polysaccharides  
Chemical modification of PSs of the commercial form of pneumo-23 (Sanofi Pasteur, France) 
was done by adding positive charge motifs in order to convert PS to zwitterionic PSs. The 
procedure of zwitterionisation was done according to a recent standardized method 
(Gallorini et al, 2007). Briefly, a chemical oxidation of the aliphatic chain from the terminal 
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NeuNAc residue using 0.01 M NaIO4, sodium metaperiodate, (Sigma, USA) for 90 min at 
room temperature was conducted leaving an aldehyde group. NaIO4 was used as limiting 
(30%) or stoechiometric (100%) reagent of the reaction. The periodate oxidation selectively 
cleaves the C8-C9 bond between vicinal hydroxyl groups (-CHOH-CH2OH) of NeuNAc 
residues, leaving an aldehyde group (-CHO) at C8. This group was converted to a cationic –
NH3+ group by reductive amination using 300 mg/ml NH4Ac, ammonium acetate, (Sigma, 
USA) and 49 mg/ml NaBH3CN, sodium cyanoborohydride, (Sigma, USA) at pH 6.5 for 5 
days at 37°C. PS obtained, R-CH2NH2, were treated with 37% formaldehyde (Merck, 
Germany) in the presence of sodium cyanoborohydride to convert the generated free amino 
group to a tertiary dimethylamine, R-CH2NH(CH3)2+ such that it retained a positive charge. 
This conversion was confirmed by the routine application of NMR spectroscopy Avance 600 
MHz (Bruker, Germany) using 5-mm triple-resonance NMR probe as evidenced by the 
resonance at 2.9 ppm. The NMRShiftDB was used for processing data obtained (Fig. 1). 
 
Fig. 1. The chemical structure of the zwitterionized polysaccharide (ZPS) of Streptococcus 
pneumoniae.  
5.1.3 The strategy of conducting in vitro assays 
The in vitro PBMC challenge with modified pneumo-23, the in vitro proliferation assay, the 
in vitro PBMC cytokine synthesis assay and the in vitro peripheral blood lymphocytes 
(PBL), part of PBMC, subsets markering assay were all conducted double blindly by two 
immunologists, the first from inside and the second from outside the research team. After 
finding that the results were minimally different between double blind runs of each assay, 
the final results were averaged. This strategy was necessary to keep the fidelity of the 
findings of the current study as this study is a pilot research on zwitterionized pneumo-23 
vaccine and because some of the novel findings in this study need to be verified prudently 
in order to avoid causal or biased results. 
5.1.4 Isolation of peripheral blood mononuclear cells 
Isolation of PBMC from the heparinized whole blood of 65 CA and 100 HC subjects was 
conducted to prepare a population of cells containing T and B lymphocytes for the 
subsequent in vitro assays. PBMC separation was carried out in ultraviolet hood. The 
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procedure was based on the gradient density sedimentation technique by using Ficoll 
hypaque (Sigma) (Wahlstorm et al., 2005). Cell viability was done; >99% of cells were found 
viable. Final concentration of the isolated PBMC suspension was adjusted to 1x106 cells/mL.  
5.1.5 PBMC challenge with modified pneumo-23 and concanavalin A  
One hundred μl of 1x106 cells/mL of PBMC suspension in complete RPMI–1640 medium 
(Merck, Germany) with 200 U/mL penicillin G (Sigma, USA), 200 µg/mL streptomycin 
(Merck, Germany), and 10% human AB serum (BDH, UK) were added to 96 wells microtiter 
plate in duplicates. Initially, cells were cultured for 1 day in a humid sterile incubator; then, 10 
μl of 40ug/mL Concanavalin A (Con A) mitogen were added as positive control, 10 μl of 5 
μg/mL diluted in PBS of modified pneumo-23 vaccine were added as test sample, and 10 μl of 
PBS alone were added as negative control. The used concentration of modified pneumo-23 
vaccine, 5 μg/mL, was adjusted repeatedly after many standardization trials. PBMC in 
complete RPMI-1640 medium were incubated with modified pneumo-23, Con A, and PBS for 
48 hours at 37 °C. Afterwards, PBMC were subjected to three in vitro assays; MTT assay to 
measure the proliferative potential of PBL, ELISA for in vitro synthesis of PBMC cytokines, IL-
2, IFN-Ǆ, and IL10, and PBL subset profiling namely, CD4, CD8, and CD21.  
5.1.6 In vitro prolifertative assay 
After 48 hours of PBMC incubation with Con A, modified penumo-23, and PBS, 40 μl of 3-
[4,5,dimethylthiazol-2-yl]-2,5diphenyl tetrazolium bromide microculture, MTT, reagent 
(Sigma, USA) at 5 mg/mL were added to the microtiter plate and incubated for 4 hours at  
37 °C. Finally, the supernatant was removed by Pasteur pipette and 100 μl of isopropanol was 
added. ELISA reader was used to measure the optical density (OD) at 540 nm Wigzell & 
Andersson, 1971). By using MTT assay, the proliferative activity of living PBMC exposed to 
mitogenic substances was measured (Shimoyama et al., 1989). The proliferative percentage of 
the challenged PBMC with Con A and zwitterionized penumo-23 was calculated in relation to 
the negative control, PBS, according to the below-mentioned equation (Kane e al., 1999): 
Proliferative % of modified pneumo-23 = [absorbency of experimental wells “PBMC 
exposed to modified pneumo-23” / absorbency of negative control wells “PBMC exposed to 
PBS”] – 1 x 100  
Proliferative % of the positive control (Con A) = [absorbency of positive control wells 
“PBMC exposed to Con A” / absorbency of negative control wells “PBMC exposed to PBS”] 
– 1 x 100. 
5.1.7 ELISA for in vitro synthesis of PBMC cytokines 
After 48 hours of PBMC incubation with modified penumo-23, Con A, and PBS, PBMC were 
centrifuged at 3000 g for 5 minutes and the supernatant was withdrawn separately. After a 
series of standardization steps, mouse monoclonal anti-human IL-2, IFN-Ǆ, and IL-10 
capturing antibodies (Dako, Denmark) were diluted 1:10 in carbonate-bicarbonate coating 
buffer (1.59g/L carbonate & 2.93 g/L bicarbonate) (Sigma, USA) at final concentration 0.1 
mg/mL. Fifty μl/well of the diluted capturing antibodies in coating buffer were added and 
incubated overnight at 4 °C. Next day after washing step, 50 μl/well of the supernatant 
diluted 1:4 in blocking buffer, bovine serum albumin (Sigma, USA), were added in 
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duplicates and the microtiter plate was incubated for 1 hour at 37 °C. Horseradish-
peroxidase-labeled rabbit monoclonal anti-human IL-2, IFN-Ǆ, and IL-10 antibodies (ICN 
immunologicals, UK) were diluted 1:100 in the antibody dilution buffer (ICN immunologicals, 
UK) at final concentration, 0.01, 0.005, and 0.0.005 mg/mL respectively. After a washing step, 
50 μl/well of the diluted horseradish-peroxidase-labeled rabbit monoclonal anti-human IL-2, 
IFN-Ǆ, and IL-10 antibodies were added and incubated for 1 hour at 37°C. The conjugated 
antibodies recognize different epitopes in IL-2, IFN-Ǆ, and IL-10 from these recognized by the 
capturing antibodies. After washing step, 50 μl/well of OPD-H2O2 as chromogen-substrate 
(Sanofi diagnostics, France) were added for 20 minutes at 37 °C. For each run, duplicate wells 
of the negative control of the run were used by adding antibody dilution buffer alone instead 
of monoclonal antibodies. ELISA readings in terms of OD were measured at wavelength 492 
nm (Schuurs & Weeman, 1977). A series of standards for IL-2, IFN-Ǆ, and IL-10 (Sigma, USA) 
were used to obtain the linear regression analysis of the resulted standard curve. Moreover, 
the median value of the standard curve was considered as the positive control of the ELISA 
run. The achieved correlation coefficient of the standard curve was 0.81 which indicated a high 
linear behavior of the customized ELISA. The minimal detection limits for IL-2, IFN-Ǆ, and IL-
10 were 0.1, 0.08, and 0.1 ng/mL, respectively. 
5.1.8 Immune phenotyping via direct immune fluorescence microscopy  
For the Fixation of PBMC cells, after 48 hours of PBMC incubation with modified penumo-
23, Con A, and PBS, PBMC were centrifuged at 3000 g for 5 minutes and the pellet was 
resuspended in PBS. Fifteen μl of 1x106 cells/mL of PBMC suspension were added onto 
circular depressions of the immunofluorescence slides. Slides were allowed to dry up for 
about 1 to 2 hours. Fifteen μl of fixative solution, which is buffered formal acetone (BFA) 
composed of 5.7% v/v PBS, 24% v/v 40 % formalin, and 43% v/v acetone from (Merck, 
Germany), were added per depression to cover all the dried lymphocytes and stored at –20 
0C for later use Taylor et al., 1970).  
For the Fluorescent microscopy, 15 μl of immunofluorescence-labeled monoclonal 
antibodies, namely anti-CD4, anti-CD8 and anti-CD21 (Dako, Denmark) diluted 1:5 in 
antibody dilution buffer (Dako, Denmark) at final concentrations 0.1, 0.1, and 0.05 mg/mL 
respectively. These antibodies were added onto slide depressions in duplicates for 1 hour at 
37 °C with mild shaking. After dipping and stirring slides in PBS-filled jar for 10 minutes, 1-
2 drops of mounting fluid were added. After adding cover slips, examination of slides was 
conducted under immunofluorescent microscope at 40X and 100X. At light microscopy 
phase, a suitable countable field was chosen to count the total number of lymphocytes. At 
UV light phase, the fluorescently stained cells were only counted. The average percentage of 
the fluorescently stained cells was calculated from the total PBL cells in 5 high power fields 
multiplied by 100 (Ben Trividi et al., 1990). 
5.1.9 Statistical analysis 
The statistical analysis was preformed using software SPSS version 10 and MS Excel 2000. 
Kolmogorov-Semirnov tests were used for confirming the normal distribution pattern of 
MTT, ELISA, and immunofluorescent CD marketing values. Therefore, mean ±SEM of the 
averaged values as well as parametric multivariate student t-tests were used to evaluate the 
significance of differences. P value <0.05 was considered significant. 
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5.2 Results 
5.2.1 The confirmation of the immunosuppression status of cancer patients 
As part of the research plan, the immunosuppression status of the involved CA patients, 
who were already shown as immunosuppressed at the clinical and laboratory hospital tests, 
was confirmed. All of the selected immunosuppressed CA patients showed significantly 
lower prolifertative rates of PBMC, lower IL-2 and IFN-Ǆ concentrations, and lower CD4+, 
CD8+, and CD21+ cells percentages than in HC (P<0.05). These comparisons are clarified as 
dashed lines between the negative control group of HC to that of CA (Fig. 2- A&B, Fig. 4- 
A&B, and Fig. 5-A&B). 
 
Fig. 2. Mean MTT OD values for negative control (PBS), zwitterionized pneumo-23 vaccine, 
and positive control (Con A) groups in both (A) CA patients and (B) healthy control subjects 
(HC). This histogram shows that pneumo-23 induces remarkable PBMC proliferation in 
immunosuppressed CA and immunocompetent HC subjects. The dashed line depicts the 
confirmed status of immune suppression represented by the significantly lower 
proliferation of un-stimulated PBMC, negative control, of CA patients than that of HC.  
5.2.2 The in vitro proliferative assay 
In this study, two groups were involved, CA and HC group. Each group was subdivided 
into three categories; test group where PBMC exposed to modified pneumo-23 vaccine, 
negative control group where PBMC cells exposed to PBS, and positive control group where 
PBMC exposed to Con A. It was found that the modified, zwitterionized, pneumo-23 
vaccine exerted remarkable stimulatory effect on PBMC proliferation of immunosuppressed 
CA patients in that the mean MTT OD value of modified pneumo-23 group in CA, 
0.48±0.033, and in HC, 0.79±0.053, were higher than in the negative control of CA, 
0.268±0.027, and of HC, 0.452±0.048 respectively (P<0.05) (Fig. 2-A and 2-B). Moreover, the 
mean MTT readings for PBMC exposed to modified pneumo-23 vaccine were close to that of 
Con A in HC, 0.85±0.1, and borderline higher than Con A in CA, 0.4±0.068 (P>0.05) (Fig. 2- 
A and B). Nevertheless, by using the calculated proliferative percentage of MTT, a 
significant difference was clear and evident between the proliferative percentage of 
modified pneumo-23 and that of Con A in immunosuppressed CA patients. The mean 
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proliferative percentage of PBMC of CA patients exposed to modified pneumo-23, 81%,±7.6, 
was significantly higher than that exposed to Con A, 51%±8.9, (P<0.05) while in HC group, 
both con A, 89%±9.6, and penum-23, 75%±8.4, were close to each other (P>0.05) (Fig. 3). In 
other words, the zwitterionized pneumo-23, unlike the unmodified penumo-23 [data not 
shown], induced efficiently a remarkable proliferation in both immunosuppressed and 
immunocompetent groups while Con A induced proliferation efficiently only in 
immunocompetent group rather than the immunosuppressed group (Figure 2). Moreover, 
there was no differences in the modified pneumo-23 or Con A -driven proliferation in 
PBMC of CA patients in respect cancer type, age, or sex of patients (P>0.05). 
 
Fig. 3. The calculated proliferative percentage of PBMC in immunosuppressed CA and 
immunocompetent HC groups in response to zwitterionized pneumo-23 vaccine and Con A 
measured by MTT assay. The proliferative percentage of PBMC exposed to zwitterionized 
penumo-23 was closely high in both CA and HC groups (P>0.05) while Con A induced 
much higher PBMC proliferation in HC than in CA group (P<0.05).  
5.2.3 The in vitro synthesis of cytokines  
ELISA for in vitro synthesis of cytokines was conducted on PBMC of both CA and HC 
groups that each was subdivided into three groups; test group, negative control, and 
positive control where PBMC were exposed to modified pneumo-23, PBS, and Con A 
respectively, for 48 hours. In CA group, it was found that the mean synthesis of soluble IL-2, 
0.61±0.063 ng/mL, and IFN-Ǆ, 0.45±0.052 ng/mL, in PBMC exposed to modified pneumo-23 
was much higher than that exposed to PBS, 0.41±0.03 and 0.29±0.051 ng/mL respectively 
and that exposed to Con A, 0.45±0.028 and 0.42±0.03 ng/mL respectively (P<0.05) (Fig. 4-A) 
while the mean synthesis of soluble IL-10, 0.36±0.042 ng/mL exposed to modified pneumo-
23 was not different from that exposed to PBS and Con A, 0.4±0.041 and 0.42±0.027 ng/mL 
respectively (P>0.05) (Fig. 4-A).  
On the other hand, in HC group, no similar upsurge was found in the mean synthesis of IL-
2, 0.67±0.061 ng/mL in PBMC exposed to modified neumo-23 when compared to the 
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negative control, 0.62±0.034 ng/mL (P>0.05) and, on contrary to CA, it was lower than in 
PBMC exposed to Con A, 0.82±0.042 ng/mL (P<0.05) (Fig. 4-B). Regarding IFN-Ǆ and IL-10, 
they were close to each other with borderline higher levels of IFN-Ǆ and IL-10 in PBMC 
exposed to modified pneumo-23, 0.52±0.031 and 0.41±0.03 ng/mL respectively than in 
PBMC exposed to PBS, 0.45±0.034 and0.37±0.052 ng/mL respectively and PBMC exposed to 
Con A, 0.47±0.042 and 0.36±0.017 ng/mL respectively (P ranged 0.051 to 0.048). (Fig. 4-B). In 
addition, there was no significant differences in the pneomo-23 and Con A -driven synthesis 
of IL-2, IFN-Ǆ, and IL-10 in PBMC of the CA patients in respect to cancer type, age, and sex 
(P>0.05). These results collectively indicated that zwitterionized pneumo-23 exerted a 
unique potent cytokine stimulatory effect, IL-2 and IFN-Ǆ, on PBMC of immunosuppressed 
cancer patients while a powerful mitogenic substance, Con A, exerted a mild cytokine 
stimulatory effect, IL-2, on immunocompetent healthy group only.  
 
Fig. 4. (A) the concentrations of in vitro synthesis of IL-2 and IFN-Ǆ but not IL-10 in CA 
PBMC exposed to zwitterionized pneumo-23 was higher than in PBMC of the negative 
control, PBS, and the positive control, Con A. (B) The concentration of IL-2 in HC PBMC 
exposed to Con A was higher than in PBMC exposed to zwitterionized penumo-23 whereas 
borderline higher IFN-Ǆ and IL-10 synthesis is seen by HC PBMC exposed to zwitterionized 
penumo-23 than by PBMC exposed to Con A. The dashed line depicts the confirmed status 
of immune suppression represented by the significantly lower synthesis of IL-2 and IFN-Ǆ 
by PBMC of the CA patients than that of negative control group of HC. 
5.2.4 The immune phenotyping of lymphocytes subsets 
The immune phenotyping of PBL exposed to modified pneumo-23, PBS, and Con A was 
investigated. Although the percentages of CD4+, CD8+, and CD21+ cells in CA group were 
lower than in HC group, these percentages were within the lowest tier of normal ranges, 30-
60% for CD4+, 20-50% for CD8+ cells, and 4-14% for CD21 [14]. IN CA, the mean percentage 
of CD8+, CD4+, and CD21+ cells in modified pneumo-23 group, 39.3±4.7, 42.7±3.2, and 
8.1±2.1% respectively, was higher than in PBS group, 25.6±3.1, 31.9±4.1, and 4.2±1.7% 
respectively, (P<0.05) and in Con A group, 27.2±2.8, 35.8±3.6, and 4.1±0.8 respectively 
(P<0.05) (Fig. 5-A) while no significant difference found between con A and PBS groups 
regarding the mean percentage of CD8+, CD4+, and CD21+ cells (P>0.05). 
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Fig. 5. (A) The mean percentage of CD8+, CD4+ and CD21+ cells was higher in CA PBMC 
exposed to zwitterionized penumo-23 than both these exposed to PBS or Con A. (B) CD4+ 
cells was higher in HC PBMC exposed to Con A than these exposed to PBS but not 
zwitterionized pneumo-23. The dashed lines depicts the confirmed status of immune 
suppression represented by the significantly higher percentages of CD8+, CD4+, and CD21+ 
cells in PBMC of the negative control group of HC than that of CA patients. 
On the other hand, there was no significant difference in the percentage of CD8+, CD4+, and 
CD21+ cells in HC PBL exposed to modified pneumo-23, 39.3±4.2, 48±5.8 and 8.3±2.2% 
respectively, when compared to cells exposed to PBS, 35.6±2.6, 45.6±3.8, and 7.8±2.4% 
respectively (P>0.05) (Fig. 5-B). However, Con A was shown to increase the percentage of 
CD4+ cells, 51.6±2.4 more than PBS group (P<0.05) and pneumo-23 (P>0.05) (Fig. 5-B). In 
addition, there was no significant differences in the percentage of CD4+, CD8+, and CD21+ 
cells in PBMC exposed to modified pneumo-23 or Con A in respect to cancer type, age, or 
sex of CA patients (P>0.05).  
5.3 Discussion 
The immunostimulatory effect of the zwitterionized pneumo-23 was tested on PBMC of 
immunosuppressed CA patients in comparison with HC group regarding the in vitro 
proliferative potential, the in vitro cytokine synthesis, IL2, IFN-Ǆ, and IL-10, and immune 
phenotyping, CD4+ as T helper cells, CD8+ as T cytotoxic/suppressor cells (Kalinski et al., 
2006; Knustion & Disis, 2005), and CD21+ as B cells (Knustion & Disis, 2005) by using the 
accurate and simple microculture tetrazolium (MTT) assay for the in vitro prolifertative 
assay (Ben Trivdei et al., 1990; Iwatsuki et al., 2004), ELISA for in vitro cytokines synthesis, 
and direct immunofluoresecence microcopy for immune phenotyping assays.  
Unlike the commercial pneumo-23 vaccine [data not shown], the chemically modified 
pneumo-23 vaccine, in a unique manner, augmented the proliferative potential of PBMC in 
both immunosuppressed, CA, and immunocompetent, HC, groups, inducing remarkable in 
vitro synthesis of PBMC soluble IL-2 and IFN-Ǆ but not IL-10 in CA versus just borderline 
increase in IFN-Ǆ and IL-10 in HC group, and augmented the proliferation of CD8+, CD4+, 
and CD21+ PBL selectively in CA rather than HC group. On contrary, the positive control, 
Con A, induced PBMC proliferation, increased in vitro synthesis of IL-2, but not IL-10 or 
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IFN-Ǆ, and increased CD4+, but not CD8+ or CD21+ cells, in immunocompetent, HC, rather 
than immunosuppressed, CA group.  
Unfortunately, no previous report was found utilizing zwitterionized pneumococcal PSs as 
enhanced immunogenic vaccine or as immunostimulatory agent to compare with. 
Nevertheless, the findings of the current research showed that the zwitterionized pneumo 
23 exerted a highly remarkable in vitro T cell dependent and/or mitogenic triggering of a 
robust immune response in just 48 hours of exposure. Moreover, in unexplained manner, 
the immunosuppression status, interestingly, did not hinder the zwitterionized pneumo-23, 
unlike Con A, to stimulate immune cells proliferation, cytokines synthesis, and PBL subsets 
proliferation and expansion. Con A, a powerful mitogenic substance, failed in triggering an 
efficient immune stimulation in immunosuppressed PBMC like that seen in 
immunocompetent PBMC. Therefore, the immune triggering pathway of the zwitterionized 
pneumo-23 might be unique.  
Collectively, the zwitterionized pneumo-23 vaccine was shown to act as a normalizing 
immunostimulatory agent for the immunosuppressed cells. In other words, it served to 
revert the suppressed 'lazy' immune cells back to normal ‘alert’ status while it did not 
stimulate much the already competent 'alert' immune cells. The findings of the current study 
might explain how the commercial pneumo-23 showed some signs of immune stimulation, 
which is most likely due to the presence of small fraction of natural zwitterionic type 1 PSs 
(Gallorini et al., 2007). Beside the report of the manufacturing company on the 
immunostimulatory effect of pneumo-23, there was a report supports the findings of the 
current research which showed that the protection of pneumo-23 vaccine after splenectomy 
was perfect against the sepsis of many bacteria other than pneumococci (Uslu et a., 2006). 
This suggests strongly the presence of non-specific immune stimulation, which was 
augmented and shown in the current study after the zwitterionisation of the commercial 
pneumo-23 vaccine 
The modified pneumo-23 vaccine was shown to stimulate the cell-mediated immunity 
(CMI) more than the humeral arm of immune response as it induced CD8+ and CD4+ cells 
far higher than CD21+ cells. These findings might render zwitterionized pneumo-23 vaccine 
as a practicable choice for stimulating the suppressed CMI in attempts to augment 
immunity against diseases. The current study also showed that the immune stimulation of 
zwitterionized pneumo-23 vaccine in CA patients was attributed partially to the synthesis of 
IL-2 and IFN- Ǆ, T helper 1 cytokines, rather than IL-10, T helper 2 cytokine, as well as 
stimulating vigorously CD8+ T cells. Collectively, this provided evidence that the 
zwitterionized pneumo-23 stimulate T-helper 1 profile of CMI. This might be supported 
indirectly by other studies which stated that the atopic bronchial asthma children, from a 
past case of outhospital pneumonia, which were given pneumo-23 vaccine showed tendency 
towards decreased level of serum IgE (Markelova et al., 2005; Ryzhov et al., 2005). This was 
either due to complete eradication of the chronic infection of pneumococcal bacteria and/or 
the deviation of the immune system towards T-helper one which counteracts the T-helper 
two atopic arm of immunity (Markelova et al., 2005; Ryzhov et al., 2005). Moreover, the 
nature of the remarkably increased CD8+ cells in response to the modified pneumo-23 was 
more likely cytotoxic rather than suppressive CD8+ cells because the enhanced prolifertative 
rate of PBMC, the in vitro high level of synthesis of IL-2 and IFN-Ǆ, and the high rates of 
CD4+ and CD21+ cells in PBMC exposed to modified penumo-23 contradict strongly the 
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possibility of the suppressive nature of CD8+ cells. Accordingly, zwitterionized pneumo-23 
more likely augments the cytotoxic arm of CMI which is essential against most of viral 
infections and tumor diseases.  
A question might be presented, whether the zwitterionized penumo-23 is an 
immunostimulatory agent or it is just an antigen that induced immune reaction. The 
findings of the current study showed that pneumo-23 mostly acts as potent 
immunostimulator as well as an effective T cell-dependent antigen rather than just an 
antigen. The findings supporting the immunostimulatory action of pneumo-23 are: first, 
peumo-23 induced consistent upsurge in PBMC proliferation, IL-2 and IFN-Ǆ synthesis, and 
CD 4+, CD8+, and CD21+ cells in immunosuppressed CA patients more than immune 
competent HC group which is exactly the contrary to what should happen in the antigenic 
stimulation. Second, the magnitude of increase in PBMC proliferation, cytokines synthesis 
and expansion percentage of PBL subsets in just 48 hours favors the immunostimulatory 
effect in addition to antigenic effect.  
The mechanism of the observed immunostimulatory action of zwitterionized pneumo-23 
vaccine has not yet been understood. It could be a combination of T cell-dependent antigen 
triggering pathway via T cell receptor (TCR), a non-specific mitogenic signal through 
bridging of multiple costimulatory receptors, or acting as a ligand on Toll-like receptors 
(TLR). A recent study revealed that TLR2 engagement in T-regulatory cells and other T-cell 
subsets with zwitterionic motifs of PS modifies functionality and activation state of these 
cells and the most effects induced by natural and chemically derived zwitterionized PS may 
be explained by their TLR2 agonist properties on T cells Wack & Gallorini, 2008). Regardless 
the previous study conclusions, the immunostimulatory effect of zwitterionized pneumo-23 
vaccine needs further studies designed specifically for investigating the mechanism and 
pathways of its immunostimulatory effect in vivo using experimental animals to explore 
why it is more evident in immunosuppressed rather than immunocompetent subjects. And 
to explore its effects on natural killer cells, antigen presenting cells, TLR, other cytokines, 
and other CD markers. Moreover, a long-term prospective study might be needed to 
evaluate the in vivo immunostimulatory effect of pneumo-23 vaccine on laboratory animals 
and later, after proving its safety, on human beings.  
Taken together, the zwitterionized, but not the commercial, pneumo-23 vaccine appeared to 
exert a remarkable in vitro immunostimulatory effect on the isolated PBMC of 
immunosuppressed cancer patients more than the immune competent individuals. In 
addition, it drives the immunity towards T-helper one profile and triggers largely CD8+ 
cells. Basing on the findings of the current study, it seems that the zwitterionized PSs exert a 
unique immunostimulatory pathway that tends to correct the immune suppression status of 
CA patients’ immune cells to normal levels while such normalizing effect was not observed 
in the immunocompetent healthy subjects. Therefore, zwitterionized PSs, such as pneumo-
23, can be developed, after securing its safety in humans, as a potent immunostimulatory 
drug for cancer immunosuppressed patients.  
6. Conclusion 
Zwitterionization can be one of the most recent approaches for immuno- stimulating 
/modulating the immune system of cancer patients. The process of zwitterionization  
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is a cheap, simple, and fast; it is a chemical procedure by which natural, non-
immunostimulating and non-immunomodulating polysaccharides are converted to 
universal TCR-based immunostimulator and immunomodulators. ZPSs are found to be 
useful in correcting the immune suppression and immune deviation in incompetent 
immune systems in cancer patients. Patients with cancer might be immunosuppressed due 
to disease itself or due to cancer chemotherapy. In both cases, correction of the immune 
system of cancer patients is necessary taken into account that fatality in cancer patients due 
to infections is very high. In addition, immune suppression itself can be considered one of 
the serious causes for the development of some tumors because of the loss of immune 
surveillance exerted by immune system which daily scavenges any cancerous neoplastic 
cells. In addition, ZPSs can be used as adjuvant elements along with other modalities of 
cancer immunotherapy to overcome the long achieved failures in this field. It is well known 
that most cases of failures in cancer immunotherapy are attributed to the ability of 
cancerous cells to escape immune defense mechanisms as well as immunotherapy 
approaches used. In this instance, ZPSs can change the fate of cancer immunotherapy to a 
more optimistic modality of therapy. One of the essential conclusions incurred from the use 
of ZPSs in cancer patients is that ZPSs exert immunostimulatory action on cancerous cells 
much more remarkably than on non-cancerous cells. The mechanism underlying this is still 
unknown; however, this implies to a very important phenomenon which might be highly 
useful in combating immune evasive nature of cancerous cells without affecting other 
normal cells. 
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